Beckman Coulter Announces Second Quarter 20...(be inline with the Company's objectives)...)

Date:7/25/2008

be in line with the Company's objectives), potential or planned investment in future growth vehicles, the full year outlook for the Company's tax rate, earnings and per share objectives, instrument placements relative to the Company's future growth potential, hardware mix, growth in the Life Sciences, Immunoassay, Chemistry, and Clinical Automation product areas, the company's expectations on expanding its installed base, and statements under the heading "Full Year Outlook," including expectations for revenue growth, operating margin, non-operating expense, pretax profit growth, tax rate, earnings per diluted share, earnings before interest, taxes, depreciation and amortization ("EBITDA"), capital expenditures, and depreciation and amortization. The outlook provided is based on fiscal year ended 2007 and the three and six months ended June 30, 2008 adjusted results and does not include special items that have or may occur in 2008.

This press release contains the Company's unaudited financial results for the three and six months ended June 30, 2008. These results may change as a result of further review by the Company's independent accountants and management. The completion of the review of our financial statements could result in additional changes to our financial results and could result in the identification of issues relating to the effectiveness of our internal control over financial reporting. Final second quarter results will be provided in the Company's quarterly report to the SEC on Form 10-Q.

Forward-looking statements included in this press release involve certain risks and uncertainties and are based on management's current expectations, estimates, forecasts and projections about the Company and are subject to risks and uncertainties, some of which may be beyond the company's control, that could cause actual results and events to differ materially from those stated in the forward-looking statements. These risks and uncertainties include, b
'/>"/>

SOURCE Beckman Coulter, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related biology technology :

1. Beckman Coulter Announces Second Quarter 2008 Earnings to be Released on Friday, July 25, 2008, Before Market Opens
2. Upcoming Beckman Coulter Investor Events Second Half of 2008
3. Beckman Coulter to Present at Upcoming Healthcare Conferences
4. Beckman Coulter Announces First Quarter 2008 Results
5. Beckman Coulter Acquires Rights to Hepatitis C Virus
6. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share
7. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
8. Beckman Coulter to Present at the 2008 Bear Stearns London Healthcare Conference
9. Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell
10. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
11. Beckman Coulter to Present at the JPMorgan Healthcare Conference